|
1
|
Landis SH, Murray T, Bolden S and Wingo
PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999.
|
|
2
|
Maldazys JD and DeKernion JB: Prognostic
factors in metastatic renal carcinoma. J Urol. 136:376–379.
1986.
|
|
3
|
Li L, Gao Y, Zhang L, Zeng J, He D and Sun
Y: Silibinin inhibits cell growth and induces apoptosis by caspase
activation, down-regulating survivin and blocking EGFR-ERK
activation in renal cell carcinoma. Cancer Lett. 272:61–69.
2008.
|
|
4
|
Dancey JE: Epidermal growth factor
receptor and epidermal growth factor receptor therapies in renal
cell carcinoma: do we need a better mouse trap? J Clin Oncol.
22:2975–2977. 2004.
|
|
5
|
Ishikawa J, Maeda S, Umezu K, Sugiyama T
and Kamidono S: Amplification and overexpression of the epidermal
growth factor receptor gene in human renal-cell carcinoma. Int J
Cancer. 45:1018–1021. 1990.
|
|
6
|
Minner S, Rump D, Tennstedt P, et al:
Epidermal growth factor receptor protein expression and genomic
alterations in renal cell carcinoma. Cancer. 118:1268–1275.
2012.
|
|
7
|
Hutson TE: Targeted therapies. Oncologist.
16(Suppl 2): 14–22. 2011.
|
|
8
|
Itsumi M and Tatsugami K: Immunotherapy.
Clin Dev Immunol. 2010:2845812010.
|
|
9
|
Yang JC, Sherry RM, Steinberg SM, et al:
Low reponse rate randomized study of high-dose and low-dose
interleukin-2 in patients with metastatic renal cancer. J Clin
Oncol. 21:3127–3132. 2003.
|
|
10
|
Velmurugan B, Gangar SC, Kaur M, Tyagi A,
Deep G and Agarwal R: Silibinin exerts sustained growth suppressive
effect against human colon carcinoma SW480 xenograft by targeting
multiple signaling molecules. Pharm Res. 27:2085–2097. 2010.
|
|
11
|
Wu KJ, Zeng J, Zhu GD, et al: Silibinin
inhibits prostate cancer invasion, motility and migration by
suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin.
30:1162–1168. 2009.
|
|
12
|
Chen PN, Hsieh YS, Chiang CL, Chiou HL,
Yang SF and Chu SC: Silibinin inhibits invasion of oral cancer
cells by suppressing the MAPK pathway. J Dent Res. 85:220–225.
2006.
|
|
13
|
Singh RP, Raina K, Sharma G and Agarwal R:
Silibinin inhibits established prostate tumor growth, progression,
invasion, and metastasis and suppresses tumor angiogenesis and
epithelial-mesenchymal transition in transgenic adenocarcinoma of
the mouse prostate model mice. Clin Cancer Res. 14:7773–7780.
2008.
|
|
14
|
Stamenkovic I: Matrix metalloproteinases
in tumor invasion and metastasis. Semin Cancer Biol. 10:415–433.
2000.
|
|
15
|
Asakuma J, Sumitomo M, Asano T, Asano T
and Hayakawa M: Modulation of tumor growth and tumor induced
angiogenesis after epidermal growth factor receptor inhibition by
ZD1839 in renal cell carcinoma. J Urol. 171:897–902. 2004.
|
|
16
|
Prewett M, Rothman M, Waksal H, Feldman M,
Bander NH and Hicklin DJ: Mouse-human chimeric anti-epidermal
growth factor receptor antibody C225 inhibits the growth of human
renal cell carcinoma xenografts in nude mice. Clin Cancer Res.
4:2957–2966. 1998.
|
|
17
|
Rowinsky EK, Schwartz GH, Gollob JA, et
al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully
human anti-epidermal growth factor receptor monoclonal antibody in
patients with metastatic renal cell cancer. J Clin Oncol.
22:3003–3015. 2004.
|
|
18
|
Motzer RJ, Amato R, Todd M, et al: Phase
II trial of antiepidermal growth factor receptor antibody C225 in
patients with advanced renal cell carcinoma. Invest New Drugs.
21:99–101. 2003.
|
|
19
|
Singh RP and Agarwal R: A cancer
chemopreventive agent silibinin, targets mitogenic and survival
signaling in prostate cancer. Mutat Res. 555:21–32. 2004.
|
|
20
|
Tyagi A, Sharma Y, Agarwal C and Agarwal
R: Silibinin impairs constitutively active TGFalpha-EGFR autocrine
loop in advanced human prostate carcinoma cells. Pharm Res.
25:2143–2150. 2008.
|
|
21
|
Singh RP, Gu M and Agarwal R: Silibinin
inhibits colorectal cancer growth by inhibiting tumor cell
proliferation and angiogenesis. Cancer Res. 68:2043–2050. 2008.
|
|
22
|
Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC
and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell
invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of
MMP-2. Carcinogenesis. 28:977–987. 2007.
|
|
23
|
Chang HR, Chen PN, Yang SF, et al:
Silibinin inhibits the invasion and migration of renal carcinoma
786-O cells in vitro, inhibits the growth of xenografts in vivo and
enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol
Carcinog. 50:811–823. 2011.
|
|
24
|
Qi L, Singh RP, Lu Y, et al: Epidermal
growth factor receptor mediates silibinin-induced cytotoxicity in a
rat glioma cell line. Cancer Biol Ther. 2:526–531. 2003.
|
|
25
|
Qiu Q, Yang M, Tsang BK and Gruslin A:
EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves
activation of both PI3K and MAPK signalling pathways. Reproduction.
128:355–363. 2004.
|
|
26
|
Tian YC, Chen YC, Chang CT, et al:
Epidermal growth factor and transforming growth factor-beta1
enhance HK-2 cell migration through a synergistic increase of
matrix metalloproteinase and sustained activation of ERK signaling
pathway. Exp Cell Res. 313:2367–2377. 2007.
|
|
27
|
Kang CS, Pu PY, Li YH, et al: An in vitro
study on the suppressive effect of glioma cell growth induced by
plasmid-based small interference RNA (siRNA) targeting human
epidermal growth factor receptor. J Neurooncol. 74:267–273.
2005.
|
|
28
|
Sumitomo M, Asano T, Asakuma J, Asano T,
Horiguchi A and Hayakawa M: ZD1839 modulates paclitaxel response in
renal cancer by blocking paclitaxel-induced activation of the
epidermal growth factor receptor-extracellular signal-regulated
kinase pathway. Clin Cancer Res. 10:794–801. 2004.
|
